Changchun High-Tech Industry (000661.SZ) subsidiary GenSci's injection solution clinical trial application has been approved.

Changchun High-Tech Industry (000661.SZ) announced that recently, its controlling subsidiary Changchun Jin Sai Pharmaceutical Co., Ltd. (referred to as "Jin Sai Pharmaceutical") received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving the domestic production drug registration clinical trial application for Jin Sai Pharmaceutical's GenSci133 injection. It is reported that GenSci133 injection is a parathyroid hormone (PTH) analog and RANKL antibody fusion protein independently developed by Jin Sai Pharmaceutical. It belongs to Class I therapeutic biological products and is intended for the treatment of osteoporosis. If the subsidiary's clinical trial application progresses smoothly, it will be beneficial for the company to diversify its business structure, optimize its product structure, enrich and improve its product line layout in the field of endocrine metabolism, and enhance the company's core competitiveness.